Immunological aspects of determination of an adequate biological treatment sequence for inflammatory bowel diseases: the expert board statement (St. Petersburg, May 22, 2021)

Cover Page


Cite item

Full Text

Abstract

On May 22, 2021, the Expert Board met in St. Petersburg to discuss their position on immunological aspects of determination of an adequate biological treatment sequence for inflammatory bowel diseases (IBD). The Expert Board aimed at discussion of current strategies, development of a consensus on determination of an adequate biological treatment sequence for IBD. The main topics of the agenda were the contribution of immune system to the pathophysiology of Crohn's disease, ulcerative colitis and their complications, efficacy of genetically engineered biological agents (GEBA) at various stages of IBD management. Participation of the leading Russian experts in IBD, as well as involvement of other specialties, made it possible to consider the topic by a multidisciplinary team, with an in-depth analysis of IBD pathophysiology, to better understand the course of the disease in some contradictory situation, for instance, when clinical remission is not associated with an endoscopically confirmed remission. One of the expected effects of this Expert Board meeting would be an improvement of GEBA administration in clinical practice, mostly due to the modification of clinical guidelines. This would ascertain and confirm the algorithms for GEBA administration for IBD, including the optimal treatment sequence depending on an agent’s mechanism of action and the patient profile. The clarification of the optimal GEBA sequence in the clinical guidelines could lead to more frequent GEBA administration in local medical clinics and institutions in the regions, where GEBA are used insufficiently due to little experience and absence of their precise positioning in the clinical guidelines.

About the authors

E. A. Belousova

Moscow Regional Research and Clinical Institute (MONIKI)

Author for correspondence.
Email: eabelous@yandex.ru
ORCID iD: 0000-0003-4523-3337

Elena A. Belousova – MD, PhD, Professor, Head of Department of Gastroenterology; Head of Chair of Gastroenterology, Postgraduate Training Faculty

61/2–9 Shchepkina ul., Moscow, 129110

 

Russian Federation

I. G. Kozlov

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology;
I.M. Sechenov First Moscow State Medical University

Email: fake@neicon.ru

Ivan G. Kozlov – MD, PhD, Professor, Head of Laboratory of Experimental and Clinical PharmacologyDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology; Professor, Chair of Medicines Organization and Management, Institute of Professional Education  I.M. Sechenov First Moscow State Medical University

1 Samory Mashela ul., Moscow, 117198, 

8/2 Trubetskaya ul., Moscow, 119991

Russian Federation

D. I. Abdulganieva

Kazan State Medical University

Email: diana_s@mail.ru
ORCID iD: 0000-0001-7069-2725

Diana I. Abdulganieva – MD, PhD, Professor, First Vicerector, Head of Chair of Hospital Therapy 

49 Butlerova ul., Kazan, 420012

Russian Federation

O. P. Alexeeva

Privolzhsky Research Medical University;
Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko

Email: fake@neicon.ru
ORCID iD: 0000-0002-1475-6584

Olga P. Alexeeva – MD, PhD, Professor, Chair of Hospital Therapy Privolzhsky Research Medical University; Director, Federal Gastroenterological Center of Povolzhye Nizhny Novgorod Regional Clinical Hospital named after N.A. Semashko

10/1 Minina i Pozharskogo ploshchad', Nizhny Novgorod, 603005, 

190 Rodionova ul., Nizhny Novgorod, 603126

 

Russian Federation

I. V. Gubonina

Military Medical Academy named after S.M. Kirov

Email: giv70@bk.ru
ORCID iD: 0000-0002-6302-7767

Irina V. Gubonina – MD, PhD, Associate Professor, 2nd Therapy Chair of Postgraduate Education 

6А Akademika Lebedeva ul., Saint Petersburg, 194044

Russian Federation

A. A. Lishchinskaya

The Loginov Moscow Clinical Scientific Center

Email: fake@neicon.ru
ORCID iD: 0000-0001-7891-2702

Albina A. Lishchinskaya – MD, PhD, Gastroenterologist, Department of Inflammatory Bowel Diseases 

86–6 Entuziastov shosse, Moscow, 111123

Russian Federation

L. V. Tarasova

I.N. Ulianov Chuvash State University;
Republican Clinical Hospital of Chuvashia

Email: fake@neicon.ru

Larisa V. Tarasova – MD, PhD, Professor, Head of Chair of Intermediate Level and Hospital Therapy, Medical Faculty I.N. Ulianov Chuvash State University; Head of Department of Gastroenterology, Head of Republican Gastroenterological Center Republican Clinical Hospital of Chuvashia

15 Moskovskiy prospekt, Cheboksary, 428015, Russian Federation;

9 Moskovskiy prospekt, Cheboksary, 428018, Russian Federation

Russian Federation

E. Yu. Chashkova

Irkutsk Scientific Centre of Surgery and Traumatology

Email: elenachash1027@yandex.ru
ORCID iD: 0000-0002-7953-6523

Elena Yu. Chashkova – MD, PhD, Coloproctologist, Leading Research Fellow, Head of Laboratory of Reconstructive Surgery, Scientific Department of Clinical Surgery 

1 Bortsov Revolyutsii ul., Irkutsk, 66400

Russian Federation

M. V. Shapina

National Medical Research Centre for Coloproctology named after A.N. Ryzhikh

Email: shapina.mv@yandex.ru
ORCID iD: 0000-0003-1172-6221

Marina V. Shapina – MD, PhD, Head of Department of Research in Inflammatory and Functional Bowel Disorders 

2 Salyama Adilya ul., Moscow, 123423

Russian Federation

O. S. Shifrin

I.M. Sechenov First Moscow State Medical University

Email: fake@neicon.ru

Oleg S. Shifrin – MD, PhD, Professor, Head of Department of Chronic Intestinal Tract and Pancreas Diseases 

8/2 Trubetskaya ul., Moscow, 119991

Russian Federation

O. B. Shchukina

Academician I.P. Pavlov First St. Petersburg State Medical University

Email: burmao@gmail.com

Oksana B. Shchukina – MD, PhD, Head of Center of Inflammatory Bowel Disease 

6–8 L'va Tolstogo ul., Saint Petersburg, 197022

Russian Federation

References

  1. Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J, Delchier JC, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Dupas JL, Carbonnel F, Bommelaer G, Coffin B, Roblin X, Van Assche G, Esteve M, Färkkilä M, Gisbert JP, Marteau P, Nahon S, de Vos M, Franchimont D, Mary JY, Colombel JF, Lémann M; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 2012;380(9857): 1909–1915. doi: 10.1016/S0140-6736(12)61084-8.
  2. Baumgart DC. Conventional medical management of ulcerative colitis: Tacrolimus. In: Baumgart D, editor. Crohn's Disease and Ulcerative Colitis. Boston: Springer; 2012. pp. 487–494. doi: 10.1007/978-1-4614-0998-4_40.
  3. Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015;110(9): 1324–1338. doi: 10.1038/ajg.2015.233.
  4. Peyrin-Biroulet L, Billioud V, D'Haens G, Panaccione R, Feagan B, Panés J, Danese S, Schreiber S, Ogata H, Hibi T, Higgins PD, Beaugerie L, Chowers Y, Louis E, Steinwurz F, Reinisch W, Rutgeerts P, Colombel JF, Travis S, Sandborn WJ. Development of the Paris definition of early Crohn's disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol. 2012;107(12): 1770–1776. doi: 10.1038/ajg.2012.117.
  5. Российская гастроэнтерологическая ассоциация, Ассоциация колопроктологов России. Язвенный колит. Клинические рекомендации. Одобрено Научно-практическим Советом Минздрава РФ. КР 193/1. 2020. 68 с. [Интернет]. Доступно на: https://ibd-care.ru/wp-content/uploads/2021/05/yazvennyj-kolit-2020.pdf.
  6. Российская гастроэнтерологическая ассоциация, Ассоциация колопроктологов России. Болезнь Крона. Клинические рекомендации. Одобрено Научно-практическим Советом Минздрава РФ. КР 176. 2020. 54 с. [Интернет]. Доступно на: https://cr.minzdrav.gov.ru/schema/176_1.
  7. Yanai H, Hanauer SB. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol. 2011;106(4): 685–698. doi: 10.1038/ajg.2011.103.
  8. Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther. 2011;33(9): 987–995. doi: 10.1111/j.1365-2036.2011.04612.x.
  9. Click B, Regueiro M. A Practical Guide to the Safety and Monitoring of New IBD Therapies. Inflamm Bowel Dis. 2019;25(5): 831–842. doi: 10.1093/ibd/izy313.
  10. Sandborn WJ, Feagan BG, Danese S, O'Brien CD, Ott E, Marano C, Baker T, Zhou Y, Volger S, Tikhonov I, Gasink C, Sands BE, Ghosh S. Safety of ustekinumab in inflammatory bowel disease: Pooled safety analysis of results from Phase 2/3 studies. Inflamm Bowel Dis. 2021;27(7): 994–1007. doi: 10.1093/ibd/izaa236.
  11. Инструкция по медицинскому применению лекарственного препарата Стелара® [Интернет]. Доступно на: https://www.janssen.com/russia/sites/www_janssen_com_russia/files/stelara_shpr_imp_31.05.2021.pdf.
  12. Vavricka SR, Rogler G, Gantenbein C, Spoerri M, Prinz Vavricka M, Navarini AA, French LE, Safroneeva E, Fournier N, Straumann A, Froehlich F, Fried M, Michetti P, Seibold F, Lakatos PL, Peyrin-Biroulet L, Schoepfer AM. Chronological order of appearance of extraintestinal manifestations relative to the time of IBD diagnosis in the Swiss Inflammatory Bowel Disease Cohort. Inflamm Bowel Dis. 2015;21(8): 1794–1800. doi: 10.1097/MIB.0000000000000429.
  13. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2001;96(4): 1116–1122. doi: 10.1111/j.1572-0241.2001.03756.x.
  14. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med. 2013;369(8): 711–721. doi: 10.1056/NEJMoa1215739.
  15. Danese S, Sandborn WJ, Colombel JF, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG. Endoscopic, radiologic, and histologic healing with vedolizumab in patients with active Crohn's disease. Gastroenterology. 2019;157(4): 1007–1018.e7. doi: 10.1053/j.gastro.2019.06.038.
  16. Vermeire S, Loftus EV, Colombel J-F, Feagan B, Sandborn W, Sands B, Danese S, D'Haens G, Kaser A, Panaccione R, Rubin D, Shafran I, O'Byrne S, Geransar P, Previtali A, Khalid JM, Kaviya A. DOP021 Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study. J Crohns Colitis. 2017;11(Suppl 1):S39. doi: 10.1093/ecco-jcc/jjx002.058.
  17. Patel KR, Lee HH, Rastogi S, Singam V, Vakharia PP, Silverberg JI. Association of psoriasis with psychiatric hospitalization in United States children and adults. Dermatology. 2019;235(4): 276–286. doi: 10.1159/000499564.
  18. Bohm M, Sagi SV, Fischer M, Kadire S, Tran G, Rahal M, Aniwan S, Meserve J, Weiss A, Kochhar G, Shashi P, Faleck D, Winters A, Chablaney S, Koliani-Pace JL, Boland B, Singh S, Hirten R, Shmidt E, Lasch K, Luo M, Hudesman D, Chang S, Lukin D, Sultan K, Swaminath A, Gupta N, Siegel CA, Kane S, Loftus EV, Sands BE, Sandborn WJ, Colombel J-F, Shen B, Dulai PS. OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis. J Crohns Colitis. 2018;12(Suppl 1):S018. doi: 10.1093/ecco-jcc/jjx180.024.
  19. Sands BE, Peyrin-Biroulet L, Loftus EV, Danese S, Colombel JF, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S. Vedolizumab shows superior efficacy versus adalimumab: results of varsity – the first head-to-head study of biologic therapy for moderate-to-severe ulcerative colitis. Gastroenterology. 2019;156(6 Suppl 1):S-81. doi: 10.1016/S0016-5085(19)36989-6.
  20. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13): 1215–1226. doi: 10.1056/NEJ-Moa1905725.
  21. Bressler B, Yarur A, Kopylov U, Bassel M, Brett N, Lissoos T, Lopez C, Natsios A, Saha S, Kifnidi C, Demuth D, Patel H, Mantzaris GJ. Clinical effectiveness of first-line anti-TNF therapies and second-line anti-TNF therapy post-vedolizumab discontinuation in patients with ulcerative colitis or Crohn’s disease. United European Gastroenterol J. 2019;7(Suppl 8): 624–625. doi: 10.1177/2050640619854671.
  22. Billmeier U, Dieterich W, Neurath MF, Atreya R. Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases. World J Gastroenterol. 2016;22(42): 9300–9313. doi: 10.3748/wjg.v22.i42.9300.
  23. Hindryckx P, Vande Casteele N, Novak G, Khanna R, D'Haens G, Sandborn WJ, Danese S, Jairath V, Feagan BG. The expanding therapeutic armamentarium for Inflammatory Bowel Disease: How to choose the right drug[s] for our patients? J Crohns Colitis. 2018;12(1): 105–119. doi: 10.1093/ecco-jcc/jjx117.
  24. Carman CV, Martinelli R. T Lymphocyte-endothelial interactions: Emerging understanding of trafficking and antigen-specific immunity. Front Immunol. 2015;6:603. doi: 10.3389/fimmu.2015.00603.
  25. Arseneau KO, Cominelli F. Targeting leukocyte trafficking for the treatment of inflammatory bowel disease. Clin Pharmacol Ther. 2015;97(1): 22–28. doi: 10.1002/cpt.6.
  26. Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14(5): 329–342. doi: 10.1038/nri3661.
  27. Kogan AN, von Andrian UH. Lymphocyte Trafficking. In: Tuma RF, Durán WN, Ley K, editors. Microcirculation. 2 nd edition. San Diego, CA: Elsevier Inc; 2008. p. 449–482.
  28. Habtezion A, Nguyen LP, Hadeiba H, Butcher EC. Leukocyte trafficking to the small intestine and colon. Gastroenterology. 2016;150(2): 340–354. doi: 10.1053/j.gastro.2015.10.046.
  29. Eksteen B, Liaskou E, Adams DH. Lymphocyte homing and its role in the pathogenesis of IBD. Inflamm Bowel Dis. 2008;14(9): 1298–1312. doi: 10.1002/ibd.20453.
  30. Silva FA, Rodrigues BL, Ayrizono ML, Leal RF. The immunological basis of inflammatory bowel disease. Gastroenterol Res Pract. 2016;2016:2097274. doi: 10.1155/2016/2097274.
  31. Bamias G, Cominelli F. Exploring the early phase of Crohn's disease. Clin Gastroenterol Hepatol. 2020:S1542-3565(20)31283-0. doi: 10.1016/j.cgh.2020.09.023.
  32. Neurath MF. Targeting immune cell circuits and trafficking in inflammatory bowel disease. Nat Immunol. 2019;20(8): 970–979. doi: 10.1038/s41590-019-0415-0.
  33. Zundler S, Becker E, Schulze LL, Neurath MF. Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances. Gut. 2019;68(9): 1688–1700. doi: 10.1136/gutjnl-2018-317977.
  34. Wyant T, Leach T, Sankoh S, Wang Y, Paolino J, Pasetti MF, Feagan BG, Parikh A. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2015;64(1): 77–83. doi: 10.1136/gutjnl-2014-307127.
  35. Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F. Immunological variables associated with clinical and endoscopic response to vedolizumab in patients with inflammatory bowel diseases. J Crohns Colitis. 2020;14(9): 1190–1201. doi: 10.1093/ecco-jcc/jjaa035.
  36. Rath T, Billmeier U, Ferrazzi F, Vieth M, Ekici A, Neurath MF, Atreya R. Effects of anti-integrin treatment with vedolizumab on immune pathways and cytokines in inflammatory bowel diseases. Front Immunol. 2018;9:1700. doi: 10.3389/fimmu.2018.01700.
  37. Veny M, Garrido-Trigo A, Corraliza AM, Masamunt MC, Bassolas-Molina H, Esteller M, Arroyes M, Tristán E, Fernández-Clotet A, Ordás I, Ricart E, Esteve M, Panés J, Salas A. Dissecting common and unique effects of anti-α4β7 and anti-tumor necrosis factor treatment in ulcerative colitis. J Crohns Colitis. 2021;15(3): 441–452. doi: 10.1093/ecco-jcc/jjaa178.
  38. Arijs I, De Hertogh G, Lemmens B, Van Lommel L, de Bruyn M, Vanhove W, Cleynen I, Machiels K, Ferrante M, Schuit F, Van Assche G, Rutgeerts P, Vermeire S. Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UC. Gut. 2018;67(1): 43–52. doi: 10.1136/gutjnl-2016-312293.
  39. Vedolizumab [summary of product characteristics]. Taastrup, Denmark: Takeda Pharma A/S; 2020.
  40. Patel H, Latremouille-Viau D, Burne R, Shi S, Adsul S. Comparison of real-world treatment outcomes with vedolizumab versus infliximab in biologic-naive patients with inflammatory bowel disease. Crohn's & Colitis 360. 2019;1(2):otz022. doi: 10.1093/crocol/otz022.
  41. Panés J, Salas A. Past, present and future of therapeutic interventions targeting leukocyte trafficking in inflammatory bowel disease. J Crohns Colitis. 2018;12(Suppl 2):S633–S640. doi: 10.1093/ecco-jcc/jjy011.
  42. Allez M, Tieng V, Nakazawa A, Treton X, Pacault V, Dulphy N, Caillat-Zucman S, Paul P, Gornet JM, Douay C, Ravet S, Tamouza R, Charron D, Lémann M, Mayer L, Toubert A. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology. 2007;132(7): 2346–2358. doi: 10.1053/j.gastro.2007.03.025.
  43. Boschetti G, Nancey S, Moussata D, Cotte E, Francois Y, Flourié B, Kaiserlian D. Enrichment of circulating and mucosal cytotoxic CD8+ T cells is associated with postoperative endoscopic recurrence in patients with Crohn's disease. J Crohns Colitis. 2016;10(3): 338–345. doi: 10.1093/ecco-jcc/jjv211.
  44. Pariente B, Cosnes J, Danese S, Sandborn WJ, Lewin M, Fletcher JG, Chowers Y, D'Haens G, Feagan BG, Hibi T, Hommes DW, Irvine EJ, Kamm MA, Loftus EV Jr, Louis E, Michetti P, Munkholm P, Oresland T, Panés J, Peyrin-Biroulet L, Reinisch W, Sands BE, Schoelmerich J, Schreiber S, Tilg H, Travis S, van Assche G, Vecchi M, Mary JY, Colombel JF, Lémann M. Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011;17(6): 1415–1422. doi: 10.1002/ibd.21506.
  45. Инструкция по медицинскому применению лекарственного препарата Энтивио® [Интернет]. Доступно на: https://www.take-da.com/4ab48e/siteassets/ru-ru/home/what-we-do/1/33/entyvio28022018.
  46. Fischer A, Zundler S, Atreya R, Rath T, Voskens C, Hirschmann S, López-Posadas R, Watson A, Becker C, Schuler G, Neufert C, Atreya I, Neurath MF. Differential effects of α4β7 and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. Gut. 2016;65(10): 1642–1664. doi: 10.1136/gutjnl-2015-310022.
  47. Briskin M, Winsor-Hines D, Shyjan A, Cochran N, Bloom S, Wilson J, McEvoy LM, Butcher EC, Kassam N, Mackay CR, Newman W, Ringler DJ. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151(1): 97–110.
  48. Lord JD, Long SA, Shows DM, Thorpe J, Schwedhelm K, Chen J, Kita M, Buckner JH. Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype. Clin Immunol. 2018;193:24–32. doi: 10.1016/j.clim.2018.05.006.
  49. Becker E, Wiendl M, Dedden M, Schulz-Kuhnt A, Atreya I, Atreya R, Neurath MF, Zundler S. Dose-dependent differential effects of vedolizumab therapy on adhesion of regulatory and effector T cells. United European Gastroenterology J. 2020;8(Suppl 8): 9. doi: 10.1177/2050640620927344.
  50. Rieder F, Fiocchi C. Intestinal fibrosis in IBD – a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol. 2009;6(4): 228–235. doi: 10.1038/nrgastro.2009.31.
  51. Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, Irving PM, Kamperidis N, Kok KB, Lamb CA, Macdonald J, Mehta S, Pollok RC, Raine T, Smith PJ, Verma AM, Jochum S, McDonald TJ, Sebastian S, Lees CW, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70(10): 1884–1893. doi: 10.1136/gutjnl-2021-324789.
  52. Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, Hart AL, Irving PM, Kok KB, Lamb CA, Limdi JK, Macdonald J, Mc-Govern DP, Mehta SJ, Murray CD, Patel KV, Pollok RC, Raine T, Russell RK, Selinger CP, Smith PJ, Bowden J, McDonald TJ, Lees CW, Sebastian S, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut. 2021;70(5): 865–875. doi: 10.1136/gutjnl-2021-324388.
  53. Bohm M, Xu R, Zhang Y, Varma S, Fischer M, Kochhar G, Boland B, Singh S, Hirten R, Ungaro R, Shmidt E, Lasch K, Jairaith V, Hudesman D, Chang S, Lukin D, Swaminath A, Sands BE, Colombel JF, Kane S, Loftus EV Jr, Shen B, Siegel CA, Sandborn WJ, Dulai PS; VICTORY Collaboration. Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Aliment Pharmacol Ther. 2020;52(4): 669–681. doi: 10.1111/apt.15921.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Belousova E.A., Kozlov I.G., Abdulganieva D.I., Alexeeva O.P., Gubonina I.V., Lishchinskaya A.A., Tarasova L.V., Chashkova E.Y., Shapina M.V., Shifrin O.S., Shchukina O.B.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies